Post-surgical liraglutide results in clinically meaningful reductions in body weight
Outcomes from the BARI-OPTIMISE randomised clinical trial, which assessed 24 weeks of liraglutide (3.0mg) as an adjunct to a lifestyle...
top of page
Browse by category
Search
AOMs help patients manage postsurgical weight recurrence
Anti-obesity medications, including semaglutide (Ozempic and Wegovy), can effectively help patients manage weight regained after...
Journal watch 29/03/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
STEP 8: Greater weight loss for once-weekly semaglutide vs daily liraglutide
Once-weekly subcutaneous semaglutide (2.4mg) is more effective on weight loss in conjunction with counselling and physical activity vs...
Saxenda approved for the treatment of obesity in adolescents
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a licence extension for Saxenda (Novo Nordisk) for the...
Liraglutide successfully targets fat that can endanger heart health
Researchers at UT Southwestern have reported that the weight-loss drug once-daily liraglutide combined with lifestyle interventions can...
Vigorous-intensity plus liraglutide maintains long-term weight loss
Researchers at University of Copenhagen and Hvidovre Hospital who examined four different types of treatment following a diet-induced...
Brain response to liraglutide may inform future treatments
A preclinical study from the Perelman School of Medicine at the University of Pennsylvania, has shown how the weight loss drug,...
IBT and liraglutide show positive results for weight loss
Intensive behavioural therapy (IBT) combined with liraglutide 3.0mg (Saxenda) can produce clinically-meaningful weight loss in patients...
Browse by tag
bottom of page